A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...